(Circulation. 1997;95:2471.)
© 1997 American Heart Association, Inc.
Articles |
the Max-Planck-Institute, Department of Experimental Cardiology, Bad Nauheim, Germany.
Correspondence to Wolfgang Schaper, MD, PhD, Max-Planck-Institute, Department of Experimental Cardiology, Benekestr 2, D-61231 Bad Nauheim, Germany.
Key Words: Editorials hepatocyte growth factor myocardial infarction ischemia
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
During the past 15 years, hepatocyte growth factor (HGF) and its receptor have been the subject of immense research efforts. The activity of HGF was first demonstrated in the serum of normal and partially hepatectomized rats by Strain et al1 and Michalopoulos et al2 in 1982. During the years 1984 to 1988, Gohda et al3 , Nakamura et al,4 Russell et al,5 and Thaler and Michalopoulos6 independently isolated and purified HGF from different sources, including platelets and serum (the history of the discovery, purification cloning, and functions of HGF are excellently reviewed by Gohda et al7 and Matsumoto and Nakamura.8 ). At that time, HGF was regarded as a growth factor specific to hepatocytes, and most researchers focused mainly on the growth of cultured hepatocytes and liver regeneration. By 1990 or 1991, the importance of HGF entered a new dimension when it was shown that HGF was identical to the scatter factor (SF),9 the fibroblast-derived tumor cytotoxic factor (F-TCF),10 and a fibroblast-derived epithelial morphogen.11 Around the same time, the HGF receptor was identified as the c-met proto-oncogene product.12 13 It became clear that HGF/SF/F-TCF is a multipotent growth factor whose receptor is not only expressed in the normal epithelium of almost every tissue but also in different cell types such as melanocytes, endothelial cells, microglial cells, neurons, hemopoietic cells, and a variety of tumor cell lines of various origins that are also targets of this growth factor.8 The general activities of HGF were found to be mitogenesis, motogenesis (enhancement of
This article has been cited by other articles:
![]() |
R. M. Day, G. Thiel, J. Lum, R. D. Chevere, Y. Yang, J. Stevens, L. Sibert, and B. L. Fanburg Hepatocyte Growth Factor Regulates Angiotensin Converting Enzyme Expression J. Biol. Chem., March 5, 2004; 279(10): 8792 - 8801. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Lenihan, A. Osman, V. Sriram, J. Aitsebaomo, and C. Patterson Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1507 - H1512. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kitta, R. M. Day, Y. Kim, I. Torregroza, T. Evans, and Y. J. Suzuki Hepatocyte Growth Factor Induces GATA-4 Phosphorylation and Cell Survival in Cardiac Muscle Cells J. Biol. Chem., February 7, 2003; 278(7): 4705 - 4712. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yasuda, Y. Goto, T. Baba, T. Satoh, H. Sumida, S. Miyazaki, and H. Nonogi Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function J. Am. Coll. Cardiol., July 1, 2000; 36(1): 115 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yasuda, Y. Goto, H. Sumida, T. Noguchi, T. Baba, S. Miyazaki, and H. Nonogi Angiotensin-Converting Enzyme Inhibition Restores Hepatocyte Growth Factor Production in Patients With Congestive Heart Failure Hypertension, June 1, 1999; 33(6): 1374 - 1378. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |